Ascendis Pharma ADR ASND

$267.07 +7.79 (3.00%)

Valuation

Market cap
16,173,106,000
Revenue TTM
$814,760,000
Net income TTM
$-258,000,000
P/E (trailing)
142.55
P/E (forward)
74.71
Profit margin
-31.67%
Debt to equity
0.31

Trading

Volume
1,281,300
Avg volume
803,208
Day's range
$258.50 – $269.85
Shares out
62,377,000
Stochastic %K
87%
Beta
0.40
Analysts
Strong Buy
Price target
$307.82

Price

Company profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipe...

Show more

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Industry
Biotechnology
Sector
Healthcare
Phone
45 70 22 22 44
Website
https://ascendispharma.com
Address
Tuborg Boulevard 12, Hellerup, Denmark

Latest news

No headlines yet.

Stocktwits

Pika_Capital Nov 12, 7:32 PM
$ASND amazing quarter. $300 Soon
0 replies
EarningsInsider Nov 12, 2:16 PM
https://www.marketbeat.com/earnings/reports/2026-11-12-ascendis-pharma-as-stock/ $ASND Ascendis Pharma A/S Earnings Transcript
0 replies
StocktwitsEarnings Nov 12, 12:53 PM
$ASND Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $1.94 up 312.77% YoY • Reported revenue of $418.71M up 67.01% YoY • Ascendis Pharma expects full-year 2026 cash flow from operating activities of at least 600M; no revenue, margin, or earnings guidance was provided in the release.
0 replies
Estimize Nov 12, 11:00 AM
$ASND reported - EPS and - revenue for Q3. http://www.estimize.com/intro/asnd?chart=historical&metric_name=eps&utm_content=ASND&utm_medium=
0 replies
Doozio Nov 9, 10:46 PM
If da 🧠 is gonna return on the DLO it’s gonna be with $XBI leading and $ASND ing as they $EXEL INTA 🐒🍌🧠⏰♾️
1 replies
Laurentium Nov 9, 4:10 AM
$ASND yes!!
0 replies
GTA_Terminal Nov 7, 9:55 AM
Dark pool check on $ASND: what traded off the exchanges this session. Price barely moved (+1.3%), which is what you'd expect if somebody big is building or unwinding a position quietly. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=ASND&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=ASND Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-activity-what-big-money-did-in-ascendis-pharma-a-s-asnd-off-the?utm_source=stocktwits&utm_medium=social
0 replies
Doozio Oct 29, 2:09 PM
It’s NUTX how wen only da 🐑 remain da 🧠 shall $ASND thru da $GLBE riding a 🦄👑
0 replies